141 related articles for article (PubMed ID: 26406950)
1. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer.
Zhang J; Yu XL; Zheng GF; Zhao F
Cancer Biomark; 2015; 15(5):609-17. PubMed ID: 26406950
[TBL] [Abstract][Full Text] [Related]
2. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study.
Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ
J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis.
Li FF; Yang Y; Wang XL; Hong YY; Wang NF; Chen ZD
Tumour Biol; 2014 Jun; 35(6):6011-20. PubMed ID: 24659425
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.
Li Y; Zhu M; Zhang X; Cheng D; Ma X
Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215
[TBL] [Abstract][Full Text] [Related]
7. Clinical effect of DAPK promoter methylation in gastric cancer: A systematic meta-analysis.
Jia W; Yu T; Cao X; An Q; Yang H
Medicine (Baltimore); 2016 Oct; 95(43):e5040. PubMed ID: 27787359
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
10. DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.
Dai L; Ma C; Zhang Z; Zeng S; Liu A; Tang S; Ren Q; Sun Y; Xu C
PLoS One; 2016; 11(12):e0167228. PubMed ID: 27907054
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
[TBL] [Abstract][Full Text] [Related]
12. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of CXCR4 and correlation with clinicopathological features and prognosis of non-small cell lung cancer patients: a meta-analysis.
Wang H; Xie F; Hu Z; Chen L
Genet Mol Res; 2015 Dec; 14(4):17893-903. PubMed ID: 26782435
[TBL] [Abstract][Full Text] [Related]
14. Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.
Duan L; Hu X; Jin Y; Liu R; You Q
BMC Cancer; 2016 Apr; 16():276. PubMed ID: 27090386
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang Y; Wu J; Huang G; Xu S
Cancer Manag Res; 2018; 10():6897-6904. PubMed ID: 30588095
[TBL] [Abstract][Full Text] [Related]
16. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
Lu C; Soria JC; Tang X; Xu XC; Wang L; Mao L; Lotan R; Kemp B; Bekele BN; Feng L; Hong WK; Khuri FR
J Clin Oncol; 2004 Nov; 22(22):4575-83. PubMed ID: 15542809
[TBL] [Abstract][Full Text] [Related]
18. Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: A meta analysis.
Shi SM; Su ZB; Zhao JJ; Yu DJ; Tu JW; Zhu JQ; Zhao JP; Sheng L; Wang SB; Sheng YJ; Chen HJ; Tian JH; Zhang Y; Wang J
J Cancer Res Ther; 2016; 12(1):277-82. PubMed ID: 27072251
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of RARβ2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer: A PRISMA-compliant meta-analysis.
Qi M; Xiong X
Medicine (Baltimore); 2018 Dec; 97(51):e13666. PubMed ID: 30572486
[TBL] [Abstract][Full Text] [Related]
20. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients.
Huang T; Chen X; Hong Q; Deng Z; Ma H; Xin Y; Fang Y; Ye H; Wang R; Zhang C; Ye M; Duan S
Sci Rep; 2015 Mar; 5():8897. PubMed ID: 25754026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
